Development and validation of a prediction model based on two-dimensional dose distribution maps fused with computed tomography images for noninvasive prediction of radiochemotherapy resistance in non-small cell lung cancer DOI Open Access
Min Zhang, Ya Li, Yongxiang Hu

et al.

Translational Cancer Research, Journal Year: 2023, Volume and Issue: 0(0), P. 0 - 0

Published: Jan. 1, 2023

There are individualized differences in the prognosis of radiochemotherapy for non-small cell lung cancer (NSCLC), and accurate prediction is essential treatment. This study proposes to explore potential multiregional two-dimensional (2D) dosiomics combined with radiomics as a new imaging marker prognostic risk stratification NSCLC patients receiving radiochemotherapy. In this study, 365 histologically confirmed NSCLC, who had computed tomography (CT) scans before treatment, received standard radiochemotherapy, Karnofsky Performance Scale (KPS) scores ≥70 were included three medical institutions, 145 cases excluded due surgery, data accuracy, poor image quality, presence other tumors. Finally, 220 study. Efficacy evaluation criteria solid tumors used evaluate efficacy. Complete partial remission indicate radiochemotherapy-sensitive group, disease stability progression radiochemotherapy-resistant group. We all then randomised them into training cohort (154 cases) validation (66 7:3 ratio. Radiomics features extracted gross tumor volume (GTV), GTV-heat, 50 Gy-heat screened. 2D model (DMGTV DM50Gy), (RMGTV), radiomics-dosiomics (RDM), models constructed, predictive performances resistance compared. Subsequently, performance various was compared by receiver operating characteristic (ROC) curves calculating sensitivity specificity. The multi-omics clinical integrated patient stratification. DM50Gy better than RMGTV DMGTV, area under curve (AUC) ROC cohorts 0.764 [95% confidence interval (CI): 0.687-0.841] 0.729 (95% CI: 0.568-0.889). And RDM performed significantly single models, AUC 0.836 0.773-0.899) 0.748 0.617-0.879), respectively. Hemoglobin level T stage independent predictors model. containing further improved both cohorts, 0.844 0.781-0.907) 0.753 0.618-0.887). Grouping according critical value revealed significant progression-free survival (PFS) overall (OS) between high-risk low-risk groups (P<0.05). Compared traditional model, demonstrates superior performance. based on data, radiomics, has effectively Through precise assessment, doctors can understand which may develop treatment optimize plans accordingly.

Language: Английский

Targeted and cytotoxic inhibitors used in the treatment of lung cancers DOI Creative Commons
Robert Roskoski

Pharmacological Research, Journal Year: 2024, Volume and Issue: unknown, P. 107465 - 107465

Published: Oct. 1, 2024

Language: Английский

Citations

4
AMPK: an energy sensor for Non-small cell lung cancer progression and treatment DOI Creative Commons

Zhengxiang Zhong,

Xuyan Wang, Ying Pan

et al.

Pharmacological Research, Journal Year: 2025, Volume and Issue: unknown, P. 107592 - 107592

Published: Jan. 1, 2025

Lung cancer (LC) is the leading cause of cancer-related morbidity and mortality in China, with non-small cell lung (NSCLC) accounting for 85% overall cases. AMP-activated protein kinase (AMPK) a key regulator energy balance homeostasis, its dysregulation common feature various malignancies, particularly NSCLC mutations Liver B1 (LKB1). Studies have shown that AMPK signalling pathway has dual role progression, both inhibiting promoting progression malignant tumours. Therefore, drugs targeting may hold significant promise therapeutic application NSCLC. This review aims to examine manifestations mechanisms by which associated molecules influence treatment. Firstly, we discuss critical importance within mutational context Secondly, We summarise related substances modulate evaluate evidence from preclinical studies on combination AMPK-targeted therapies address issue drug resistance under current clinical treatments. In summary, this paper highlights developing enhance efficacy NSCLC, as well potential applying these therapy overcome resistance.

Language: Английский

Citations

0
Editorial: Recent advancements in RNA-based and targeted therapeutics DOI Creative Commons
Yiming Meng, Viola Bianca Serio, Yuquan Tong

et al.

Frontiers in Genetics, Journal Year: 2025, Volume and Issue: 16

Published: April 8, 2025

Language: Английский

Citations

0
ANÁLISE DE ESTRATÉGIAS TERAPÊUTICAS PARA O ONCOGENE KRAS EM CÂNCER DE PULMÃO DE CÉLULAS NÃO PEQUENAS DOI Open Access

J. F. Silva,

THELE ALBUQUERQUE DA SILVA, Walter Luiz Lima Neves

et al.

Revista Foco, Journal Year: 2024, Volume and Issue: 17(12), P. e7087 - e7087

Published: Dec. 4, 2024

O câncer de pulmão é subdividido em carcinoma pulmonar pequenas células (CPPC) e não (CPCNP), o CPCNP engloba aproximadamente 85% dos diagnósticos. Devido a alta incidência do CPCNP, necessário esclarecer suas características moleculares relacionadas ao processo carcinogênese. Nesse contexto, mutação KRAS apresenta um papel significativo para evolução da neoplasia por apresentar percentual aproximado 33% estar envolvido no proliferação, diferenciação apoptose celular. Objetivo: Explorar atividade proteína diante das abordagens tratamento eficientes voltadas pequenas. Metodologia: estudo refere-se uma revisão crítica literatura que contém como base dados Scientific Eletronic LibrLY Online (SciELO), Pubmed Google Acadêmico com artigos abordam tema dentro período 2019 2024. Resultados: Foram avaliados 110 artigos, quais 21 foram selecionados análise terapias utilizadas relação oncogene atualizações, relevância receptor fator crescimento epidermal (EGFR) os progressos na tecnologia anticorpos monoclonais.Conclusão: revisou acerca direcionadas às mutações pequenas, destacou sua relevância. Também discutidos avanços emprego monoclonais, bem carcinogênese inibição proliferação

Citations

0
Development and validation of a prediction model based on two-dimensional dose distribution maps fused with computed tomography images for noninvasive prediction of radiochemotherapy resistance in non-small cell lung cancer DOI Open Access
Min Zhang, Ya Li, Yongxiang Hu

et al.

Translational Cancer Research, Journal Year: 2023, Volume and Issue: 0(0), P. 0 - 0

Published: Jan. 1, 2023

There are individualized differences in the prognosis of radiochemotherapy for non-small cell lung cancer (NSCLC), and accurate prediction is essential treatment. This study proposes to explore potential multiregional two-dimensional (2D) dosiomics combined with radiomics as a new imaging marker prognostic risk stratification NSCLC patients receiving radiochemotherapy. In this study, 365 histologically confirmed NSCLC, who had computed tomography (CT) scans before treatment, received standard radiochemotherapy, Karnofsky Performance Scale (KPS) scores ≥70 were included three medical institutions, 145 cases excluded due surgery, data accuracy, poor image quality, presence other tumors. Finally, 220 study. Efficacy evaluation criteria solid tumors used evaluate efficacy. Complete partial remission indicate radiochemotherapy-sensitive group, disease stability progression radiochemotherapy-resistant group. We all then randomised them into training cohort (154 cases) validation (66 7:3 ratio. Radiomics features extracted gross tumor volume (GTV), GTV-heat, 50 Gy-heat screened. 2D model (DMGTV DM50Gy), (RMGTV), radiomics-dosiomics (RDM), models constructed, predictive performances resistance compared. Subsequently, performance various was compared by receiver operating characteristic (ROC) curves calculating sensitivity specificity. The multi-omics clinical integrated patient stratification. DM50Gy better than RMGTV DMGTV, area under curve (AUC) ROC cohorts 0.764 [95% confidence interval (CI): 0.687-0.841] 0.729 (95% CI: 0.568-0.889). And RDM performed significantly single models, AUC 0.836 0.773-0.899) 0.748 0.617-0.879), respectively. Hemoglobin level T stage independent predictors model. containing further improved both cohorts, 0.844 0.781-0.907) 0.753 0.618-0.887). Grouping according critical value revealed significant progression-free survival (PFS) overall (OS) between high-risk low-risk groups (P<0.05). Compared traditional model, demonstrates superior performance. based on data, radiomics, has effectively Through precise assessment, doctors can understand which may develop treatment optimize plans accordingly.

Language: Английский

Citations

0